Company Overview: EXEL

Upcoming Projects (EXEL)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (EXEL)

Discussing the use of Exelixis' cabozantinib to treat advanced neuroendocrine tumors
Ticker: EXEL
Executed On: Sep 18, 2024 at 01:00 PM EDT

Expired Projects (EXEL)

Investigating Loxo’s larotrectinib in treating TRK cancers with upcoming data in Q4
Tickers: LOXO, EXEL, RXDX, NVS
Execute By: Dec 12, 2017

Upcoming & Overdue Catalysts (EXEL)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (EXEL)

Exelixis (EXEL) Announces Cabozantinib Progression-Free Survival Data from COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
Ticker: EXEL
Occurred on: Dec 21, 2020
Takeda's(TAK) CABOMETYX (cabozantinib) Approved in Japan for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
Tickers: TAK, EXEL
Occurred on: Nov 27, 2020
Phase 1b COSMIC-021 Trial data of Exelixis'(EXEL) Cabozantinib + atezolizumab (TECENTRIQ) in Solid tumors to be presented February 13, 2020 at ASCO GU
Ticker: EXEL
Occurred on: Feb 10, 2020
Exelixis’ (EXEL) Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
Ticker: EXEL
Occurred on: Sep 21, 2018
Top-Line Phase 3 Data of cabozantinib (CELESTIAL trial) for Patients with Advanced Hepatocellular Cancer (HCC) Due 2017
Ticker: EXEL
Occurred on: Oct 16, 2017
Exelixis (EXEL) and Bristol-Myers Squibb (BMY) Present Phase 1 Data on CABOMETYX + Opdivo in Genitourinary Tumors at European Society for Medical Oncology 2016 Congress
Tickers: EXEL, BMY
Occurred on: Oct 11, 2016
Exelixis (EXEL) Presents Phase 2 CABOSUN Results Analyzing Cabozantinib Versus Pfizer's (PFE) Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
Ticker: EXEL
Occurred on: Oct 10, 2016
Exelixis (EXEL) and Bristol-Myers Squibb (BMY) to Present Phase 1b Data on Cobimetinib + Vemurafenib + Atezolizumab in Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma Monday October 10th
Tickers: EXEL, BMY
Occurred on: Oct 10, 2016
European Commission Approves Exelixis' (EXEL) Cabometyx for Treatment of Adults With Advanced Renal Cell Carcinoma
Tickers: EXEL, IPSEY
Occurred on: Sep 14, 2016
Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy
Tickers: EXEL, IPN.PA
Occurred on: Jul 22, 2016
Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting
Tickers: EXEL, RHHBY
Occurred on: Jun 05, 2016
Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO
Tickers: EXEL, I7G.F
Occurred on: Jun 05, 2016
Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
Ticker: EXEL
Occurred on: May 23, 2016
Exelixis Announces FDA Approval of CABOMETYX (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Ticker: EXEL
Occurred on: Apr 25, 2016
Exelixis' cabozantinib NDA for advanced kidney cancer gets Priority Review, action date (PDUFA) set for June 22
Ticker: EXEL
Occurred on: Apr 25, 2016

Strategic Initiatives (EXEL)

Exelixis (EXEL) Transfers Canadian Cabometyx Rights to Ipsen (IPSEY), Retains Rights in U.S and Japan
Tickers: EXEL, IPSEY
Announcement Date: Dec 21, 2016

EXEL Overview